Targeted Therapies for Pediatric and Young Adult Glioma
Official title: Targeted Therapies for Glioma
Funded at Brigham and Women's Hospital · NIH-11417207 · Data updated 2026-11-12
A funded program aims to develop brain-tumor treatments that specifically target genetic drivers in children and young adults with glioma.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Brigham and Women's Hospital NIH-funded |
| Lab location | 1 site (Boston, United States) |
| Project start | September 19, 2013 |
| Project end | August 31, 2029 |
| Funding year | 2026 |
| Award (this year) | $2,441,596 |
| NIH project number | 5P50CA165962-13 |
| Project ID | NIH-11417207 on NIH RePORTER |
Who could benefit from this research
✓Could help
Eligible patients include children and young adults with glioma, especially those with BRAF-driven tumors or diffuse midline gliomas, who may benefit from targeted therapies.
✕Less likely to help
Patients without BRAF-driven gliomas or those whose tumors do not respond to the studied targeted agents may see limited or no benefit.
What this research studies
This grant supports collaboration between basic scientists and clinicians across major Boston institutions to create targeted therapies for pediatric and young adult gliomas. The project focuses on BRAF-related drivers and other oncogenic vulnerabilities, using brain-penetrant inhibitors and non-invasive tools to predict who will benefit. It also explores innovative approaches for the deadliest form, diffuse midline glioma, aiming to identify new drug targets and testing strategies that can cross the blood-brain barrier. Overall, the effort combines laboratory discoveries with translational efforts to move promising therapies toward patients who need them.
Why it matters
Potential benefit: If successful, this work could lead to more effective, brain-penetrant treatments for children and young adults with glioma and reduce treatment-related side effects through better patient selection.
How similar studies have gone: Prior work has established potential targeted approaches and brain-penetrant inhibitors, with ongoing efforts to optimize response and prediction.
Where this research is happening
-
Brigham and Women's Hospital
Boston, United States Active
Researchers
- Principal investigator: Batchelor, Tracy T — Brigham and Women's Hospital
- Study coordinator: Batchelor, Tracy T
Related research
Other NIH-funded projects on the same topics.
-
Next‑gen oncolytic virus therapy for glioblastoma targeting AKT and ERK
A new cancer therapy using an engineered oncolytic virus to fight glioblastoma by blocking AKT/ERK signals and boosting the body’s immune response, with potential to reduce seizures and improve quality of life.
-
Bone marrow immune cells and glioma progression in teens and young adults
A study in adolescents and young adults with brain tumors looks at how immune cells from bone marrow may influence the progression from low-grade to high-grade gliomas.
-
How RNA Splicing Might Shape Glioma Cell States and Therapy Response
A small NIH-funded project will study how alternative RNA splicing influences glioma cell identities and treatment resistance in patient-derived cells.
-
Liquid biopsy for monitoring high-grade glioma using patient-specific DNA junctions
A Mayo Clinic team tests a blood test that looks for unique tumor DNA pieces in glioblastoma patients to monitor disease without frequent scans.
-
Deciphering how a brain cell pH helper influences glioma growth
A study is exploring whether a brain cell pH regulator (Slc4a4) affects the growth and blood vessel changes of malignant glioma to identify new angles for treatment.
-
Predicting how gene therapy spreads in glioblastoma after surgery to improve treatment coverage
This project uses a gene therapy that helps radiation work better against glioblastoma and builds computer models to predict where the therapy reaches after surgical tumor removal.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.